APP and fragile X syndrome: Genetic reduction of APP/Aβ could partially or completely correct characteristic fragile X phenotypes, including audiogenic seizures, anxiety, dendritic spine morphology and exaggerated mGluR-LTD (Westmark et al., 2011), suggesting drugs directed at reducing Aβ in Alzheimer disease such as the secretase inhibitors or β-site APP cleaving enzyme (BACE-1) inhibitors may be applicable to fragile X syndrome (Malter et al., 2010; Westmark, 2013; Westmark et al., 2013).